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Abstract
Self and Mauritsen (1988) developed a sample size determination procedure for
score tests in generalized linear models under contiguous alternatives. Its perfor-
mance may deteriorate when the effect size is large. We propose a modification of the
Self-Mauritsen method by taking into account of the variance of the score statistic
under both the null and alternative hypotheses, and extend the method to nonin-
feriority trials. The modified approach is employed to calculate the sample size for
the logistic regression and negative binomial regression in superiority and noninferi-
ority trials. We further explain why the formulae recently derived by Zhu and Lakkis
tend to underestimate the required sample size for the negative binomial regression.
Numerical examples are used to demonstrate the accuracy of the proposed method.
Keywords: Exemplary dataset; Negative binomial regression; Noninferiority trials; Power
and sample size; Score confidence interval
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1 Introduction
Generalized linear models (GLM) have been commonly used in the analysis of biomedical
data (Nelder and Wedderburn, 1972; McCullagh and Nelder, 1989). Statistical inference
in GLMs is often based on the Wald test and the likelihood ratio (LR) test. However, the
Wald and LR tests can be liberal in small and moderate samples. In the comparison of
two binary proportions, the Wald and LR methods can be anti-conservative under some
parameter configurations even when the sample size reaches 200 (Laud and Dane, 2014)
because the logistic regression overestimates the odds ratio in these studies (Nemes et al.,
2009). Similar phenomenon is observed in the analysis of over-dispersed count data using
the negative binomial (NB) regression (Aban et al., 2009). The score test has been recom-
mended to control the type I error rate when the sample size is relatively small. In fact,
many widely used methods such as Pearson’s chi-squared test, Cochran-Mantel-Haenszel
test and Wilcoxon rank sum test are score tests from GLMs.
One concern about the score test is its lower power when compared to the Wald test. In
fact, the score test can sometimes be more powerful than the Wald test. Xing et al. (2012)
observed that the Wald test from the logistic regression may often miss rare disease-causal
variants that can be identified by other asymptotic tests in large case-control association
studies. Table 1 presents two scenarios for comparing two binomial proportions on the
risk difference metric, in which the score test has higher power than the Wald test. The
first scenario tests for superiority when the sample sizes are unbalanced in the two groups.
In scenario 2, a noninferiority (NI) test is considered under balanced sample sizes. The
results also evidence that it may sometimes be inappropriate to use the power calculation
procedure developed for the Wald test to estimate the power of the score test, and vice
versa. Technical details on the score test and the exact power calculation can be found in
Farrington and Manning (1990) and Tang (2019).
Self and Mauritsen (1988) developed a power and sample size calculation procedure for
the score test from GLMs under sequences of contiguous alternatives (Cox and Hinkley,
1974). This method generally works well for alternatives close to the null hypothesis. Its
accuracy may degrade when the group sample sizes are unbalanced or when the effect size
is large (Self et al., 1992). Self and Mauritsen’s approach approximates the variance of the
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group size true proportion exact power (%)
n1 n0 p1 p0 Hypothesis score
(a) Wald(b) Wald2(b)
60 30 0.1 0.3 H0 : p1 ≥ p0 vs H1 : p1 < p0 67.33 60.81 65.28
80 80 0.35 0.4 H0 : p1 ≥ p0 + 0.15 vs H1 : p1 < p0 + 0.15 75.37 74.05 -
Table 1: Two scenarios with higher power in the score test than in the Wald test
(a) Score test defined in equation (3) of Farrington and Manning (1990)
(b) Wald (Z = pˆ1−pˆ0−M0√
pˆ1(1−pˆ1)/n1+pˆ0(1−pˆ0)/n0
) and Wald2 (Z = log{[pˆ1/(1−pˆ1)]/[pˆ0/(1−pˆ0)]}√
[n1pˆ1(1−pˆ1)]−1+[n0pˆ0(1−pˆ0)]−1
) are the
Wald tests from the binomial regression respectively with identity and logit link functions
score statistic under the null hypothesis by the variance under the alternative hypothesis.
This assumption is asymptotically correct under contiguous alternatives, but unlikely to
hold at alternatives that are not close to the null hypothesis (Self and Mauritsen, 1988).
We propose a modification of Self and Mauritsen’s procedure by taking into account
of the variance of the score statistic under both the null and alternative hypotheses. It
can greatly improve the performance of the method. For example, Tang (2011) obtained
the sample size formula for Wilcoxon rank sum test for ordinal outcomes on basis of the
asymptotic variance of the U statistic under both hypotheses, which shows improvements
over the formulae derived under contiguous alternatives (Whitehead, 1993; Zhao et al.,
2008). Similar ideas were employed by Farrington and Manning (1990) in the comparison
of binary proportions in NI trials. In these simple cases, the score test and its asymp-
totic distribution can be obtained analytically. In this paper, we consider more complex
situations where the model contains some nuisance parameters. The score test has been
commonly used in the superiority trials. It is less well known how to use the score method
to analyze the NI trials. In Section 2, we explain how to conduct the NI tests in GLM
based on the score method, and introduce the modified sample size procedure for both
superiority and NI trials via the exemplary dataset approach.
The proposed method is employed to estimate the sample size for the score test from
the NB regression in Section 3, and for the score test from the logistic regression with
categorical covariates in Section 4. The performance of the proposed method is assessed
by numerical examples and compared with some existing procedures.
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2 Score tests in GLM
2.1 Score test and score confidence interval
In GLMs, the scalar response variables y1, . . . , yn are assumed to have probability density
functions of the form (Nelder and Wedderburn, 1972; McCullagh and Nelder, 1989)
f(yi|xi, zi, β,α, φ) = exp
[
yiθi − b(θi)
a(φ)
+ c(yi, φ)
]
, (1)
where θi is the canonical parameter and φ is the dispersion parameter. The mean of yi is
µi =
∂b(θi)
∂θi
, and its variance is Vi =
∂µi
∂θi
a(φ). We assume that the covariates are related to
the mean µi via a link function ηi = βxi +α
′zi = g(µi), where xi is a scalar covariate, the
vector zi contains other covariates including the intercept, and (β,α) are the regression
coefficients. In the analysis of clinical trials, xi = 0 or 1 is the treatment status.
Suppose we are interested in testing the hypothesis
H0 : β = β0 vs H1 : β 6= β0.
Let
Sβn(β,λ)
Sλn(β,λ)
 =
∑ni=1 ∂ log[f(yi|xi,zi,β,λ)]∂β∑n
i=1
∂ log[f(yi|xi,zi,β,λ)]
∂λ
 be the score function, and
In(β,λ) =
Iββn(β,λ) I ′βλn(β,λ)
Iβλn(β,λ) Iλλn(β,λ)
 the expected information matrix, where the subscript
n refers to the sample size, and λ = (α
′, φ) is the vector of nuisance parameters. Let
λˆ = (αˆ, φˆ) be the maximum likelihood estimate (MLE) under the restriction of β = β0.
That is, n−1Sλn(β0, λˆ) = 0.
The score statistic for testing H0 : β = β0 can be written as (Cox and Hinkley, 1974)
Z(β0) =
Sβn(β0, λˆ)√
Vn
=
Sβn(β0, λˆ)√
Iββn(β0, λˆ)− I ′βλn(β0, λˆ)I−1λλn(β0, λˆ)Iβλn(β0, λˆ)
. (2)
The null hypothesis is rejected if |Z(β0)| ≥ z1−α/2, where zp is the pth percentile of N(0, 1).
As will be illustrated in Section 3, the score test can be used to test the hypothesis in
superiority and NI trials by setting β0 as the superiority and NI margin. The confidence
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interval (CI) is often reported to quantify the uncertainty in the estimated effect. The
(1− α)100% score CI for β can be obtained by inverting the score test
{β : |Z(β)| ≤ z1−α/2}.
Statistical decision can be made equivalently based on the score CI. The null hypothesis is
rejected if the score CI does not contain the null hypothesis value.
2.2 Asymptotic distribution of the score statistic
The score test and its asymptotic distribution usually have explicit analytic expressions
in the simple two-group comparison if the model does not contain an unknown dispersion
parameter. Please refer to Farrington and Manning (1990) and Tang (2019) for examples.
We consider more general cases where the vector of nuisance parameters λ contains other
parameters in addition to an intercept term.
In general, λˆ is not a consistent estimate of λ under the restriction of β = β0. It will
converge to the limiting value λ∗ defined as the solution to the following equation (Self and
Mauritsen, 1988)
lim
n→∞
E[n−1Sλn(β0, λˆ)] = 0. (3)
We estimate λ∗ by adapting the method of Lyles et al. (2007). We firstly construct an
exemplary dataset consisting of records for every possible combination of the covariates and
outcomes. Each record has a weight that represents the frequency of the covariate and out-
come in the population. A weighted regression is fitted to the exemplary dataset using the
standard statistical software. We assume that all covariates are categorical. A continuous
covariate can be discretized using a large number of categories. Suppose there are a finite
number of distinct covariate configurations {(zk, xk); k = 1, ...,m}, and the proportion of
each configuration is pik in the population. Suppose the response variable takes J possible
values (y1, . . . , yJ). We can estimate λ
∗ by fitting the null model to the following dataset
with mJ observations, where wkj = pik Pr(Y = yj|xk, zk, β,λ) is the weight attached to
each observation, and the total weight in all observations is
∑m
i=1
∑J
j=1wij = 1.
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x1 z1 y1 w11
. . .
x1 z1 yJ w1J
. . .
xm zm y1 wm1
. . .
xm zm yJ wmJ
Lyles et al. (2007) approach is slightly different. It requires a much larger dataset, and
can only estimate the power at a given sample size. The total weight in Lyles et al. (2007)
approach is equal to the total sample size N . Let’s give a simple example of comparing two
binary proportions with Pr(y = 1|x = 1) = 0.8 and Pr(y = 1|x = 0) = 0.4. Suppose N =
100, and 75% patients are assigned to the experimental arm (x = 1). Then (m, J) = (2, 2).
Our approach includes 4 observations: (x = 1, y = 1, w = 0.6), (x = 1, y = 0, w = 0.15),
(x = 0, y = 1, w = 0.1) and (x = 0, y = 0, w = 0.15). In Lyles et al. (2007) approach, the
dataset consists of 200 pseudo-observations with 75 copies of (x = 1, y = 1, w = 0.8) and
(x = 1, y = 0, w = 0.2) for subjects in the experimental arm, and 25 copies of (x = 0, y =
1, w = 0.4) and (x = 0, y = 0, w = 0.6) for placebo subjects. If observations with the same
(x, y) are combined by adding up their weights, the dataset in Lyles et al. (2007) approach
becomes a dataset with four observations (x = 1, y = 1, w = 60), (x = 1, y = 0, w = 15),
(x = 0, y = 1, w = 10) and (x = 0, y = 0, w = 15). The ratio of the weights for observations
with the same (x, y) is N : 1 between Lyles et al. (2007) approach and our approach.
Our method is more convenient and potentially more accurate than Lyles et al. (2007)
approach. In Lyles et al. (2007) method, one needs to guess the sample size, construct
the exemplary dataset, fit the null model and estimate the power at the given sample size.
The whole process needs to be repeated if the sample size changes. In theory, λ∗ remains
unchanged, and the noncentrality parameter of the Wald, Score or LR test or its square
change proportionally if we increase or decrease the total sample size. Therefore, the power
and sample size calculation can be implemented by first fitting the model at a fixed sample
size, and then using analytic methods to adjust the noncentrality parameter and solve the
power or sample size equations accordingly. We fit the null model using SAS Proc Genmod
with the FREQ option to incorporate the weight. One shall not use the Weight option in
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the Genmod procedure since it is used to adjust for the dispersion parameter. Because the
Genmod procedure truncates the weight to an integer, we multiply all the weights by a
large value (say 109) to minimize the effect of truncation. Lyles et al. (2007) fits the model
at the sample size for the trial, which is typically small (i.e. below 1, 000). The weight
after truncation in Lyles et al. (2007) method may no longer represent the frequency of the
covariate and outcome in the population, and the estimation of λ∗ can be inaccurate.
In Self and Mauritsen (1988), an exemplary dataset contains m records for all possible
combinations of the covariates, where the weight is the frequency of the covariates, and
the response outcome is the expected value of response at the covariate configuration. The
data structure may not be acceptable by some statistical software packages, and does not
allow the estimation of the dispersion parameter φ∗.
In GLMs, the inference is made by assuming the covariates are known and fixed, but
the covariates are typically unobserved at the design stage of a clinical trial. For example,
although gender is fixed for each patient, it will be treated as unknown at the design
stage since we do not know which patients will be enrolled. We firstly derive the mean
and variance of the score statistic given the covariates, which are then averaged over all
possible combinations of the covariates.
Let S(k)(β,λ) =
S(k)β (β,λ)
S
(k)
λ (β,λ)
 =
∂ log[f(yi|xk,zk,β,λ)]∂β
∂ log[f(yi|xk,zk,β,λ)]
∂λ
 denote the contribution to the
score function from a subject with covariate (xk, zk). Let E
(k) and V (k) represent, respec-
tively, the mean and variance of S(k)(β0,λ
∗) under the true model (1). Let E = (Eβ, Eλ)′ =∑m
k=1 pikE
(k) and V =
∑m
k=1 pikV
(k). Note that Eλ = 0 by equation (3). The asymptotic
distribution of (Sβn(β,λ
∗), Sλn(β,λ
∗))′ is given by
n1/2
n−1Sβn(β,λ∗)− Eβ,
n−1Sλn(β,λ
∗)− Eλ
 ∼ N(0, V ). (4)
Let J (k)(β,λ) = −
∂2 log[f(yi|xk,zk,β,λ)]∂β2 ∂2 log[f(yi|xk,zk,β,λ)]∂β∂λ′
∂2 log[f(yi|xk,zk,β,λ)]
∂β∂λ
∂2 log[f(yi|xk,zk,β,λ)]
∂λ∂λ′
 denote the contribution to
the observed information matrix from a subject with covariate (xk, zk). Let I˜
(k)(β0,λ
∗) be
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the expectation of J (k)(β0,λ∗) under the true model (1), and I˜(β0,λ∗) =
I˜ββ(β0,λ∗) I˜ ′βλ(β0,λ∗)
I˜βλ(β0,λ
∗) I˜λλ(β0,λ∗)
 =∑m
k=1 pikI˜
(k)(β0,λ
∗). By the Taylor series expansion, we get
n−1/2Sβn(β0, λˆ) ≈ n−
1
2Sβn(β0,λ
∗)− I˜ ′βγ(β0,γ∗) I˜−1γγ (β0,γ∗)n−
1
2Sγn(β0,γ
∗). (5)
Combining equations (4) and (5) yields the asymptotic distribution of the score statistic
n
1
2 [n−1Sβn(β0, λˆ)− Eβ] ∼ N(0, σ21), (6)
where σ21 = AV A
′, A = [1,−I˜ ′βγ(β0,γ∗) I˜−1γγ (β0,γ∗)]. In the special case considered
by Self and Mauritsen (1988), I˜(β0,λ
∗) is identical to the Fisher information matrix
I(β0,λ
∗) =
Iββ(β0,λ∗) I ′βλ(β0,λ∗)
Iβλ(β0,λ
∗) Iλλ(β0,λ∗)
 for the exemplary dataset under H0, and therefore
A = [1,−I ′βγ(β0,γ∗) I−1γγ (β0,γ∗)].
As n→∞, the null variance n−1Vn = n−1[Iββn(β0, λˆ)−I ′βλn(β0, λˆ)I−1λλn(β0, λˆ)Iβλn(β0, λˆ)]
converges in probability to
σ20 = Iββ(β0,λ
∗)− I ′βγ(β0,λ∗)I−1λλ(β0,λ∗)Iβλ(β0,λ∗). (7)
2.3 Power and Sample Size formulae
The power of the score test (2) is given by
P = Φ
(√
n|Eβ|√
σ21
− z1−α
2
√
σ20
σ21
)
, (8)
where Φ(·) is the standard normal cumulative distribution function, and σ20 and σ21 are
defined in equations (6) and (7). Inverting (8) yields the sample size
Nnew =
(z1−α/2σ0 + zPσ1)2
E2β
. (9)
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Self and Mauritsen (1988) method is formulated on basis of the noncentral chi-squared
distribution, and the power and sample size estimates can be well approximated by
PSM = Φ
(√
n|Eβ|√
σ21
− z1−α
2
)
,
NSM =
(z1−α/2 + zP )2σ21
E2β
.
(10)
It assumes σ20 ≈ σ21. The assumption holds under a sequence of contiguous alternatives.
Self et al. (1992) showed that the performance of the Self and Mauritsen (1988) procedure
may degrade when the effect size is large or when the group sample sizes are unbalanced.
It is generally easier to compute σ20 than σ
2
1. Under contiguous alternatives, the power
and sample size can also be calculated as
Ps0 = Φ
(√
n|Eβ|√
σ20
− z1−α
2
)
,
Ns0 =
(z1−α/2 + zP )2σ20
E2β
.
(11)
3 Sample size for NB regression
The NB regression has been widely used to analyze overdispersed count data and recurrent
event data. The NB distribution can be written as a Poissongamma mixture. If Y follows a
Poisson distribution with mean µ, where  is gamma distributed with mean 1 and variance
κ, the marginal distribution of Y is NB(µ, κ)
Pr(Y = y|µ, κ) = Γ(y + 1/κ)
y!Γ(1/κ)
[
κµ
1 + κµ
]y [
1
1 + κµ
]1/κ
, y = 0, 1, 2, . . . , (12)
where Γ(·) is the Gamma function.
Suppose in a trial, n subjects are assigned randomly to either the experimental (g = 1)
or control (g = 0) treatment group. Let ng be the number of subjects in group g. We assume
the planned treatment duration is τc for each subject, but subjects may discontinue the
study with the loss-to-follow-up distribution G(t). Let ti be the follow-up time, and yi the
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number of events for subject i. Then yi|gi = g, ti ∼ NB(λgti, κ), where λg is the event rate
in group g.
Suppose a lower event rate indicates better health status. In a superiority trial, the pur-
pose is to demonstrate that the experimental treatment can reduce the event rate relative
to the control treatment. The hypothesis can be written as
H0 :
λ1
λ0
= 1 vs H1 :
λ1
λ0
< 1. (13)
In a NI trial, the objective (Tang, 2017, 2018b) is to show that the test treatment is
not materially less efficacious than a standard control treatment by proving λ1/λ0 < M0,
where M0 is the prespecified margin that is bigger than 1, but close to 1. The hypothesis
can be written as
H0 :
λ1
λ0
= M0 vs H1 :
λ1
λ0
< M0. (14)
Mathematically, the superiority trial can be viewed as a special case of the NI trial by
setting M0 = 1.
Let β = log(λ1/λ0), β0 = log(M0) and α = log(λ0). Since µi = α + log(ti) + gi log(M0)
under H0, the null model can be easily fitted using standard software packages (e.g. SAS
Proc Genmod) by setting the offset as log(ti) for subjects in the control group, and log(M0ti)
for subjects in the experimental arm. The score test can be written as
Zs =
∑
{i:gi=1}
yi−µˆi
1+κˆµˆi√
dˆ0dˆ1
dˆ0+dˆ1
, (15)
where µˆi = exp(αˆ + β0gi)ti, and dˆg =
∑
{i:gi=g} µˆi/(1 + κˆµˆi) for g = 0 and 1.
The power and sample size can be calculated using the procedure described in Section
2. The expressions for the score function, observed and expected information matrix are
given in equations (2.3)-(2.8) in Lawless (1987). In our implementation, the continuous
time to follow-up is approximated by a categorical variable with L = 100 levels
t =
tL = τc with probability pL = 1−G(τc)tl = G−1 (pL(l−0.5)L−1 ) with probability (1− pL)/(L− 1) for l = 1, . . . , L− 1. (16)
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The final result is insensitive to the choice of L if L is not too small. We allow the
loss-to-follow-up distribution to differ by the treatment group. There are m = 2L possible
combinations of the values for the treatment and time to follow-up. We truncate the number
of response categories at a large number J = 200 so that Pr(yij ≥ J) < 10−5. The full
exemplary dataset consists of mJ observations. The weights for the mJ = 2LJ observations
are calculated according to the treatment allocation ratio and the true distribution defined
in equation (12). It requires the specification of the dispersion parameter κ and the event
rates for each group. As mentioned in Section 2.2, we multiply all the weights by a large
value (say 109) to minimize the effect of truncation since the SAS Genmod procedure
truncates the weight to an integer.
When all subjects have equal follow-up time (tgj ≡ t), the method can be slightly
simplified with m = 2. In this paper, we focus on the analysis of recurrent events. The
simplified procedure is also suitable for other types of overdispersed counts such as the
number of magnetic resonance imaging lesions in multiple sclerosis trials. Let µg and y¯g
be, respectively, the expected and observed mean count in group g. For recurrent events,
µg = λgt. The score test (15) reduces to
Ws =
y¯1 −M0y¯0√
n−11 (µˆ1 + κˆµˆ
2
1) + n
−1
0 (µˆ0 + κˆµˆ
2
0)
, (17)
where µˆ1 = M0µˆ0 is the MLE under H0. Test (17) is similar to the test (equation (7))
of Farrington and Manning (1990) for assessing the relative risk between two binomial
proportions. In this special case, the sample size in the control arm is
n0 =
[
z1−α/2
√
θ−1(µ∗1 + κ∗µ
∗2
1 ) + (µ
∗
0 + κ
∗µ∗20 ) + zP
√
θ−1(µ1 + κµ21) + (µ0 + κµ
2
0)
]2
(µ1 −M0µ0)2 , (18)
where θ = n1/n0 and (µ
∗
0, µ
∗
1, κ
∗) can be estimated by the exemplary dataset method. In
superiority trials, we can approximate (µ∗0, µ
∗
1, κ
∗) by the method of moments,
µ∗0 = µ
∗
1 = µ¯ =
θµ1 + µ0
θ + 1
and κ∗ =
κ(θµ21 + µ
2
0)
(θ + 1)µ¯2
+
θ(µ1 − µ0)2
(θ + 1)2µ¯2
, (19)
11
Figure 1: Plot of the chi-square statistic (Z2(β) from the score test) as a function of M0 in
a CGD trial
where κ∗ > κ if µ1 6= µ0, and κ∗ is the solution to
n1
E(y1 − µ∗1)2
µ∗1(1 + κ∗µ
∗
1)
+ n0
E(y0 − µ∗0)2
µ∗0(1 + κ∗µ
∗
0)
= n1 + n0.
It would be interesting to compare the proposed method with that recently developed
by Zhu and Lakkis (2014) and Zhu (2017) for superiority and NI trials because they use a
similar idea to the score test. The approaches of Zhu and Lakkis (2014) and Zhu (2017)
are based on the statistic log(µˆ1/µˆ0)− log(M0) instead of the score statistic
n0 =
[
z1−α/2
√
1
µ∗∗0
+ 1
θµ∗∗1
+ 1+θ
θ
κ+ zP
√
1
µ0
+ 1
θµ1
+ 1+θ
θ
κ
]2
[log(µ1/µ0)− log(M0)]2
, (20)
where κ is assumed to be known, a = −κM0(1 + θ), b = κ(µ0M0 + θµ1) − (1 + θM0),
c = µ0 + θµ1, and µ
∗∗
0 = ([−b −
√
b2 − 4ac]/2a and µ∗∗1 = M0µ∗∗0 are the limiting values
of the restricted MLE at given κ. Zhu and Lakkis (2014) and Zhu (2017) implicitly make
two approximations. Firstly, the follow-up time is set to their mean values (i.e. ti = t¯)
for all individuals, leading to underestimated variance of log(µˆ1/µˆ0)− log(M0) under both
H0 and H1 (this can be proved by using the inequality in Appendix A.2 of Tang (2015)).
Secondly, it approximates κ∗ by κ, and the null variance of log(µˆ1/µˆ0)− log(M0) is usually
underestimated since κ∗ obtained under the null hypothesis in the score approach tends to
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be larger than κ particularly when the treatment effect is large. This is shown in equation
(19) for superiority trials when all subjects have equal follow-up time. The phenomenon
is analogous to the comparison of two groups with continuous outcomes, in which the
variance estimate based on the pooled outcomes yi0 ∼ N(µ0, σ2) and yi1 ∼ N(µ1, σ2) tends
to overestimate the true variance if the mean difference is ignored. Therefore Zhu-Lakkis’s
approach tends to underestimate the sample size. In superiority trials (M0 = 1) with equal
treatment allocation, Zhu-Lakkis’s sample size estimate is strictly smaller than the lower
sample size bound of Tang (2015) for the Wald test from the NB regression (Tang, 2017).
Below we present several examples to illustrate the proposed method.
Example 1 Chronic granulomatous disease (CGD) is a rare inherited disorder of the im-
mune system, characterized by recurrent pyogenic infections. Suppose we plan to design a
two-arm CGD trial to assess the effect of an experimental treatment on the infection rate.
Some parameters are estimated from a CGD trial analyzed by Matsui (2005) and Tang
(2018a). The historical trial enrolled n = 128 eligible patients. It was terminated early
for efficacy based on an interim analysis. In the trial, 14 (22.2%) out of 63 patients in the
gamma interferon group and 30 (46.2%) out of 65 patients on placebo had at least one
serious infection. We analyze the number of repeated infections using the NB regression.
The event rate ratio between two treatments based on the Wald statistic is 0.3566 (95%
CI: [0.1934, 0.6575]). Figure 1 plots the chi-square statistic (i.e. Z2(β) from the score test)
as a function of M0. The score CI is [0.1957, 0.6681], which corresponds to the region
{β : Z2(β) ≤ z21−α/2 = 3.814}. The score CI is slightly wider than the Wald CI.
We estimate the sample size at the following parameter values. The infection rate
is λ0 = 1.1 infections per year in the control arm, and κ = 0.9, which are close to the
unconstrained MLE (λˆ0 = 1.07, κˆ = 0.91) from the analysis of the historical CGD trial.
Suppose the experimental treatment can reduce the infection rate by 60% (i.e. λ1/λ0 = 0.4).
The target power is 80% or 90%, and the two-sided significance level is α = 0.05. The
treatment allocation ratio is 1 : 1. The planned treatment duration is τc = 1 or 3 years
for each subject, but subjects may discontinue the trial early with a wc = 25% chance and
the loss to follow-up is exponentially distributed. We also assess the performance of the
proposed method at other parameter values (λ0 = 0.8, κ = 1.2, wc = 0).
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We compare several sample size procedures for the NB regression. In Zhu and Lakkis
(2014), three methods were proposed to evaluate the variance of the test statistic under H0.
We evaluate only the approach recommended by the authors, in which the null variance
is calculated based on the approximate restricted MLE. The sample size estimate by Tang
(2015) method for the Wald test is also presented for the purpose of comparison. Table 2
reports sample size estimates at the target power, and the power estimates at the sample size
Nnew determined by equation (9). The simulated power is evaluated based on 160, 000 trials.
There is more than 95% chance that the simulated power lies within 2
√
0.8 ∗ 0.2/160000 =
0.2% and 2
√
0.9 ∗ 0.1/160000 = 0.15% of the true power respectively when the target
power is 80% and 90%. Because the estimated sample size is rounded up to the nearest
integer, the nominal power by the proposed method at Nnew is slightly larger than the
target power. The proposed method yields the nominal power estimate that is generally
within 1% of the simulated power, evidencing the accuracy of the proposed method.
Because the treatment effect is quite large (λ1/λ0 = 0.4), the variances of the score
statistic under H0 and H1 are not close. Self and Mauritsen’s method (equation (10))
underestimates the required size while formula (11) overestimates the sample size. Tang
(2017, 2018b) demonstrates that the method of Zhu and Lakkis (2014) underestimates
the required size if the follow-up time varies across patients. Table 2 indicates that Zhu-
Lakkis’s formula still underestimates the sample size and overestimates the power even if
all patients have equal follow-up time. At the target 90% power, the sample size estimates
are quite close for the Wald and score tests. But at the target 80% power, the score test
requires about 7.0% to 8.5% more subjects than the Wald test when λ0 = 1.1, τc = 3 and
wc = 0 or 25% in this example.
Example 2 We compare the proposed method, Self and Mauritsen’s procedure and Zhu
(2017) approach for the sample size determination in NI trials. For the purpose of illustra-
tion, we set λ0 = 1.0 or 1.5, wc = 0 or 25%, κ = 1, λ1/λ0 = 0.8 or 1, and M0 = 1.25. In
practice, one typically assumes the true rate ratio is 1 or close to 1 in designing a NI trial.
If the experimental treatment is truly more effective than the control treatment, but the
treatment effect is relatively small (e.g. true rate ratio = 0.8), a NI trial may be chosen
if it is infeasible to run a superiority trial that requires a much larger sample size. If the
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NI test is significant, one may continue to conduct a superiority test to assess whether
the experimental treatment is more effective than the control treatment. In this example,
we focus on determining the sample size and power for the NI test. The simulated power
is evaluated based on 160, 000 trials. There is more than 95% chance that the simulated
power lies within 2
√
0.8 ∗ 0.2/160000 = 0.2% of the true power.
Table 3 reports sample size estimates at the target P = 80% and 90% power and
α = 0.05. Since the NI test is one-sided, the actual type I error rate is α/2 = 0.025.
Because the treatment effect is smaller in NI trials than in superiority trials, the differences
in the sample size estimates from various methods reduce in NI trials, but the general
pattern is similar to that in Example 1.
4 Sample size for logistic regression
Self and Mauritsen (1988) investigated the sample size estimation for comparing two bino-
mial proportions (gi = 0 or 1) using logistic regression while controlling for a categorical
covariate zi with S = 2 levels. We call zi a stratum variable, and revisit the problem with
S ≥ 2 strata. Suppose for subjects in stratum s, yi follows a Bernoulli distribution with
the probability of success
Pr(yi = 1|gi, zi = s) = exp(α0 + αs + βgi)
1 + exp(α0 + αs + βgi)
=
1
1 + exp(−α0 − αs − βgi) , (21)
where exp(α0) is the odds at gi = 0 in stratum 1, exp(β) is the odds ratio associated with
the group status gi among subjects from the same stratum, and exp(αs) is the odds ratio
for subjects in stratum s relative to subjects with the same gi from stratum 1 (α1 = 0).
Model (21) can be used to analyze data from both perspective clinical trials and ret-
rospective case-control studies. The objectives are different, but the underlying statistical
problems are similar in the two types of studies. Table 4 displays the data format for both
studies. In a clinical trial, we compare the proportion of responders between two treatment
groups, where xgs is the number of responders among ngs subjects assigned to treatment
group g in stratum s. In the case-control study, the aim is to compare the proportion of
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exposed between the case and control groups, where xgs is the number of exposed subjects
among ngs case (g = 1) or control (g = 0) subjects in stratum s.
In fact, the score test for testing H0 : β = 0 has explicit analytic expression
Z =
∑S
s=1
ns1ns0
ns
(pˆs1 − pˆs0)√∑S
s=1
ns1ns0
ns
p¯s(1− p¯s)
, (22)
where pˆsg = xsg/nsg, ns = ns0 + ns1, and p¯s = (xs0 + xs1)/ns. The power and sample size
formulae in Section 2.3 can be used by setting
Eβ =
S∑
s=1
tsρs(1− ρs)(ps1 − ps0),
σ20 =
S∑
s=1
tsρs(1− ρs)p∗s(1− p∗s),
σ21 =
S∑
s=1
tsρs(1− ρs)[(1− ρs)ps1(1− ps1) + ρsps0(1− ps0)],
(23)
where psg = E(pˆsg) is the true response rate, n =
∑S
s=1 ns is the total sample size, ts =
ns
n
is
the proportion of subjects contributed by stratum s, ρs =
ns1
ns
is the proportion of subjects
from group g = 1 in stratum s, and p∗s = ρsps1 + (1 − ρs)ps0. The technical details are
omitted here. We will extend the method to sample size determination for the stratified
score tests in superiority, NI and equivalence trials on basis of the risk difference, relative
risk or odds ratio effect measures in Tang (2019), and a general proof will be presented in
that paper. The score statistic (22) is identical to Cochran (1954) statistic, and the power
formula (8) is identical to that derived by Nam (1992) for Cochran’s test although Nam
(1992) considered only the case-control studies.
We conduct two simulation studies to compare several methods.
Example 3 Suppose there are two strata. Let (Π1,Π2,Π3,Π4) denote respectively the
proportion of subjects with (gi, zi) = (0, 1), (0, 2), (1, 1) and (1, 2). Thus t1 = Π1 + Π3,
t2 = Π2 + Π4, ρ1 =
Π3
t1
and ρ2 =
Π4
t2
. We set (Π1,Π2,Π3,Π4) = (.25, .25, .25, .25) and
(.4, .1, .1, .4). The odds ratio associated with the stratum is exp(α1) = 2, and the odds
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ratio for the exposure is exp(β) = 2 or 3. The overall response rate in the study population
µ¯ =
Π1
1 + exp(−α0) +
Π2
1 + exp(−α0 − α1) +
Π3
1 + exp(−α0 − β) +
Π4
1 + exp(−α0 − α1 − β)
is set to 0.15 and 0.5, which is used to derive α0. The set up is similar to that reported in
Table 2 of Self and Mauritsen (1988).
Table 5 displays the power and sample size results at the target power 80%, 90% and
95%, and two-sided type I error 0.05. The analytic expression (10) gives the same sample
size estimates as that reported in table 2 of Self and Mauritsen (1988) in all cases at µ¯ = 0.5,
but slightly larger estimates in all cases at µ¯ = 0.15 possibly due to rounding errors. This
verifies the validity of the power and sample size calculation based on the simpler equation
(23) in the logsitic regression. The simulated power is estimated at the sample size Nnew
from the proposed method based on 106 simulated datasets. There is more than 95% chance
that the simulated power lies within 2
√
0.8 ∗ 0.2/106 = 0.08% of the true power.
All methods perform well possibly because the sample sizes are balanced overall between
two groups (Pr(g = 1) = Pr(g = 0) = 0.5) although when (Π1,Π2,Π3,Π4) = (.4, .1, .1, .4),
the sample sizes are highly unbalanced between two groups within each stratum. We
compare the methods by assessing how close the estimated nominal power is to the empirical
power at a given sample size. There are more cases with > 1% difference between the
nominal and simulated power estimates by formulae (10) and (11) than by formula (8).
In nearly all cases at (Π1,Π2,Π3,Π4) = (.4, .1, .1, .4), the nominal power by formula (8) is
closer to the simulated power than that by equation (10).
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dropout event power (%) at Nnew
proportion rate total sample size estimates nominal power
wc (%) λ0 κ τc Nnew NSM Ns0 ZL
(a) Wald(b) SIM(c) Pnew PSM Ps0 ZL
(a)
target power 80%
0 1.1 0.9 3 58 38 68 51 54 80.85 80.29 93.83 73.59 84.74
0 1.1 1.2 3 70 46 82 63 65 80.80 80.48 93.57 73.96 84.38
0 0.8 0.9 3 65 44 76 58 61 80.91 80.10 92.87 73.96 84.52
0 0.8 1.2 3 77 52 89 69 73 80.84 80.24 92.77 74.17 84.22
0 1.1 0.9 1 96 72 107 86 94 81.05 80.22 89.94 75.71 84.20
0 1.1 1.2 1 108 81 121 97 105 80.88 80.17 90.22 75.51 84.02
0 0.8 0.9 1 117 93 128 105 116 81.15 80.17 88.48 76.38 83.95
0 0.8 1.2 1 129 101 143 117 127 81.02 80.09 88.87 76.09 83.82
25 1.1 0.9 3 64 42 74 54 59 81.07 80.60 93.42 74.21 86.36
25 1.1 1.2 3 76 51 88 65 71 80.62 80.38 93.04 74.17 85.77
25 0.8 0.9 3 72 50 83 61 68 80.93 80.20 92.33 74.39 85.92
25 0.8 1.2 3 85 58 97 73 80 81.03 80.51 92.39 74.72 85.85
25 1.1 0.9 1 108 83 120 94 105 81.12 80.26 89.43 76.03 85.22
25 1.1 1.2 1 121 92 135 105 117 81.12 80.28 89.76 75.87 85.24
25 0.8 0.9 1 132 106 144 116 131 81.10 80.11 87.95 76.56 84.73
25 0.8 1.2 1 145 115 159 127 143 80.87 80.07 88.38 76.31 84.79
target power 90%
0 1.1 0.9 3 74 50 91 69 72 89.88 90.41 97.69 83.30 91.97
0 1.1 1.2 3 89 61 109 84 87 89.75 90.37 97.52 83.50 91.65
0 0.8 0.9 3 83 59 101 78 82 89.90 90.16 97.20 83.65 91.81
0 0.8 1.2 3 98 70 119 93 97 89.60 90.12 97.11 83.72 91.54
0 1.1 0.9 1 124 97 143 116 125 90.25 90.17 95.73 85.53 91.79
0 1.1 1.2 1 139 108 162 131 140 89.93 90.07 95.83 85.24 91.60
0 0.8 0.9 1 152 124 172 143 155 90.50 90.13 94.96 86.28 91.72
0 0.8 1.2 1 167 135 191 158 170 90.24 90.02 95.13 85.92 91.57
25 1.1 0.9 3 81 56 99 73 79 89.88 90.26 97.39 83.54 92.91
25 1.1 1.2 3 97 68 118 88 95 89.80 90.34 97.29 83.82 92.72
25 0.8 0.9 3 92 66 111 83 91 89.99 90.16 96.92 84.05 92.80
25 0.8 1.2 3 108 78 130 98 107 89.73 90.18 96.88 84.13 92.64
25 1.1 0.9 1 139 111 160 127 141 90.27 90.02 95.36 85.68 92.41
25 1.1 1.2 1 156 123 180 142 157 90.15 90.13 95.59 85.61 92.49
25 0.8 0.9 1 172 142 193 157 175 90.48 90.13 94.69 86.53 92.33
25 0.8 1.2 1 189 154 213 172 192 90.24 90.17 94.96 86.34 92.40
Table 2: Estimated sample size at the target 90% power and estimated power for the score
test from NB regression in superiority trials
(a) Method 3 of Zhu and Lakkis (2014). It estimates the null variance of the test statistic
based on the approximate restricted MLE.
(b) Sample size estimate by Tang (2015) method for Wald test is displayed for comparison
(c) Simulated power (SIM) are evaluated at Nnew based on 160, 000 simulated datasets.
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dropout event true power (%) at Nnew
proportion rate rate total sample size estimates nominal power
wc (%) λ0 ratio κ Nnew NSM Ns0 Zhu
(a) Wald(b) SIM(c) Pnew PSM Ps0 Zhu
(a)
0 1.0 0.8 1 337 313 348 334 335 79.93 80.02 82.92 78.76 80.41
0 1.5 0.8 1 278 253 290 275 276 79.88 80.02 83.63 78.45 80.47
25 1.0 0.8 1 377 351 388 361 375 80.15 80.10 82.77 78.93 81.76
25 1.5 0.8 1 308 282 319 293 306 80.09 80.09 83.46 78.62 82.00
0 1.0 1.0 1 1264 1244 1272 1264 1262 80.01 80.02 80.62 79.76 80.01
0 1.5 1.0 1 1053 1031 1063 1053 1051 80.07 80.01 80.84 79.65 80.02
25 1.0 1.0 1 1407 1388 1416 1360 1405 79.85 80.00 80.55 79.77 81.33
25 1.5 1.0 1 1161 1139 1171 1117 1160 79.95 80.01 80.78 79.68 81.53
Table 3: Estimated sample size at the target 80% power and estimated power for the score
test from NB regression in NI trials
(a) Method 3 of Zhu (2017). It estimates the null variance of the test statistic based on the
approximate restricted MLE.
(b) Sample size estimate by Tang (2015) method for Wald test is displayed for comparison
(c) Simulated power (SIM) are evaluated at Nnew based on 160, 000 simulated datasets.
Clinical trials Case-control study
z = 1 z = S z = 1 z = S
placebo active . . . placebo active exposure control case . . . control case
Event g = 0 g = 1 . . . g = 0 g = 1 status g = 0 g = 1 . . . g = 0 g = 1
Yes x10 x11 . . . xS0 xS1 exposed x10 x11 . . . xS0 xS1
No n10 − x10 n11 − x11 . . . nS0 − xS0 nS1 − xS1 No n10 − x10 n11 − x11 . . . nS0 − xS0 nS1 − xS1
Sum n10 n11 . . . nS0 nS1 Sum n10 n11 . . . nS0 nS1
Table 4: Binary outcomes from stratified clinical trials and case-control studies
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Example 4 Self et al. (1992) observed that the Self and Mauritsen (1988) method degrades
when the sample sizes are highly unbalanced between two groups. In this simulation, the
set up is similar to that reported in Table 1 of Self et al. (1992). We set pi = Pr(g = 1) =
0.05, 0.5, 0.75, Pr(Z = 2|g = 1) = 0.8, and Pr(Z = 2|g = 0) = 0.2. Thus (Π1,Π2,Π3,Π4) =
(0.8(1− pi), 0.2(1− pi), 0.2pi, 0.8pi). Note that pi = 0.5 (0.75) corresponds to the 1 : 1 (3 : 1)
treatment allocation ratio, which is commonly used in clinical trials. The scenario pi = 0.05
may arise in case-control studies or in genetic studies when a small proportion of subjects
carry the risk genotypes (Tang, 2011). The true odds ratio is exp(α1) = 2 for stratum and
exp(β) = 2 for exposure. The overall response rate in the study population
µ¯ =
Π1
1 + exp(−α0) +
Π2
1 + exp(−α0 − α1) +
Π3
1 + exp(−α0 − β) +
Π4
1 + exp(−α0 − α1 − β)
is set to 0.02 and 0.15. Because the sample size estimates vary greatly by methods, we
evaluate the nominal power and empirical power based on 106 simulations at both the
sample sizes from the proposed and Self and Mauritsen (1988) methods. We repeat the
simulation for unstratified score tests without adjustment for the stratum effect when there
is no confounding effect (α1 = 0), where α0 is the solution to
µ¯ =
pi
1 + exp(−α0 − β) +
1− pi
1 + exp(−α0) .
Table 6 displays the power and sample size results. The nominal power by formula (8)
is very close to the simulated power, but formulae (10) and (11) may produce very poor
power estimates which can deviate from the simulated power by 16% in some cases.
5 Discussion
We propose a modification of the Self and Mauritsen (1988) method for sample size calcu-
lation for score tests from GLMs, and extend it to the NI trials. The modification takes
into account of the fact that the variance of the score statistic differs under H0 and H1.
The proposed method is also suitable for other regression models. For example, the binary
outcome is often analyzed by the logistic regression on basis of the odds ratio between two
21
target estimated size power (%) at Nsw power (%) at Nnew
pi µ¯ α0 power(%) Nnew Nsw Ns0 SIM Pnew PSM Ps0 SIM Pnew PSM Ps0
No confounding or stratum effect: p(y = 1|z, g) = 11+exp[−α0−g log(2)]
.05 .02 −3.9398 80 11661 17232 9601 91.07 90.97 80.00 96.35 80.08 80.00 63.48 87.03
90 16537 23069 12853 96.27 96.23 90.00 99.14 90.06 90.00 78.36 95.70
.15 −1.7776 80 2035 2626 1805 88.37 88.04 80.00 92.22 80.02 80.00 69.37 84.51
90 2826 3516 2416 94.99 94.71 90.01 97.45 90.27 90.00 82.80 93.90
.50 .02 −4.2951 80 3587 3581 3589 80.63 79.95 80.01 79.92 80.69 80.01 80.07 79.99
90 4800 4794 4804 90.55 89.97 90.00 89.94 90.59 90.00 90.04 89.98
.15 −2.1230 80 536 531 539 80.48 79.64 80.05 79.47 80.37 80.01 80.41 79.84
90 717 711 721 90.18 89.78 90.04 89.62 90.42 90.03 90.28 89.86
.75 .02 −4.4502 80 5879 4651 6451 69.37 68.91 80.00 66.24 80.73 80.00 88.30 76.26
90 7636 6226 8636 83.20 82.47 90.00 78.59 90.46 90.00 94.84 86.17
.15 −2.2845 80 840 697 906 72.33 71.50 80.04 69.08 80.52 80.02 86.81 76.99
90 1097 933 1213 84.85 84.33 90.03 81.17 90.24 90.00 94.02 86.95
Confounding: p(y = 1|z, g) = 11+exp[−α0−z log(2)−g log(2)]
.05 .02 −4.1643 80 9752 13078 8473 89.38 88.95 80.00 93.58 80.43 80.00 67.70 85.21
90 13621 17507 11343 95.48 95.19 90.00 98.06 90.41 90.00 81.57 94.43
.15 −1.9777 80 1943 2269 1811 85.58 85.33 80.01 88.02 80.30 80.00 73.66 82.69
90 2659 3037 2425 93.54 93.19 90.00 95.24 90.39 90.01 85.84 92.43
.50 .02 −4.7609 80 6096 5596 6317 76.89 76.40 80.00 75.08 80.46 80.00 83.25 78.59
90 8068 7492 8456 88.09 87.68 90.00 86.24 90.37 90.00 91.98 88.62
.15 −2.5597 80 882 853 894 79.37 78.69 80.03 78.15 80.69 80.04 81.32 79.49
90 1175 1142 1197 89.59 89.18 90.02 88.63 90.32 90.02 90.81 89.49
.75 .02 −4.9868 80 10398 8795 11127 72.84 72.48 80.00 70.22 80.46 80.00 86.14 77.29
90 13618 11773 14896 85.45 85.01 90.00 82.17 90.42 90.00 93.65 87.27
.15 −2.8044 80 1419 1271 1486 76.01 75.27 80.03 73.62 80.46 80.00 84.17 78.18
90 1872 1701 1989 87.46 86.92 90.01 85.04 90.35 90.00 92.52 88.20
Table 6: Power and sample size estimate for the score test from logistic regression with
unequal group sample sizes
[1] Simulated power (SIM) are evaluated at Nnew based on 1000, 000 simulated datasets.
groups. Now suppose the parameter of interest is the relative risk instead of the odds ratio.
The method is still suitable if the model is reparametrized in terms of the response rate in
the control group and the relative risk parameter (Tang, 2019).
The proposed method shows a marked improvement over the Self and Mauritsen (1988)
formula in logistic and NB regressions when either the treatment effect is large or sample
sizes are unbalanced in the two groups. In these situations, the Self and Mauritsen (1988)
method degrades because the variance of the score statistic can be quite different under
H0 and H1. As illustrated in Section 3, the approaches of Zhu and Lakkis (2014) and Zhu
(2017) for NB regression tend to underestimate the size 1) when there is a large variation
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in the patients’ follow-up time, and/or 2) when there is a large treatment effect.
The sample size calculation for the score test requires the construction and analysis
of an exemplary dataset if the model is complex, and there is no analytic solution for
the restricted MLE under the null hypothesis. The main computation time lies in the
analysis of the exemplary data, and this can usually be done within few minutes. It is
much quicker than the simulation method, which requires the generation and analysis of
at least thousands of datasets in order to get a quite precise power estimate at a given
sample size. As evidenced by the results in Tables 1 and 2, the sample size procedure shall
be consistent with the test used for the analysis (Zhu and Lakkis, 2014). Otherwise, the
study may be either underpowered or overpowered. We recommend using the proposed
procedure (or a simplified version if it exists) to determine the sample size if one plans to
analyze the trial using the score test.
A future research direction is to extend the exemplary dataset approach to the Wald
test and score test (Liu and Liang, 1997) from the generalized estimating equations (GEE)
in the analysis of repeated measurements. The sample size calculation is complicated even
for the Wald test in GEEs because there are missing outcomes, and the working correlation
structure may be different from the true correlation structure. Even if the analytic formula
exists by using the independent or true correlation structure, the calculation can still be
complex to account for missing data. In the exemplary dataset approach, one can get the
noncentrality parameter for the Wald test directly through the analysis of the exemplary
data. The generation of the exemplary data also provides an opportunity to verify whether
the sample size assumption is correct for correlated outcomes.
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